M. Kreuter (Heidelberg, Germany), A. Tzouvelekis (Athens, Greece)
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases J. Lipner (Warsaw, Poland), M. Lissy (Neu-Ulm, Germany), B. Dymek (Warsaw, Poland), K. Dzwonek (Warsaw, Poland), P. Dobrzanski (Warsaw, Poland), M. Kania (Warsaw, Poland), A. Golebiowski (Warsaw, Poland), S. Pikul (Warsaw, Poland)
| |
Usefulness of surgical lung biopsies after cryobiopsies when pathological results are unspecific or show a pattern suggestive of a nonspecific interstitial pneumonia B. Bondue (Belgium), T. Pieters (Brussels, Belgium), A. Froidure (Brussels, Belgium), V. Heinen (Liège, Belgium), P. Alexander (Ronse, Belgium), D. Hoton (Liège, Belgium), F. Dome (Liège, Belgium), M. Remmelink (Brussels, Belgium), D. Leduc (Brussels, Belgium)
| |
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON B. Crestani (Paris, France), M. Quaresma (Ingelheim am Rhein, Germany), M. Kaye (Minneapolis, Minnesota, United States of America), T. Ogura (Yokohama, Kanagawa, Japan), W. Stansen (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), M. Kreuter (Heidelberg, Germany)
| |
Proof of concept of a non-invasive screening tool to detect idiopathic pulmonary fibrosis (IPF) in an early stage J. De Backer (Antwerp, Belgium), C. Van Holsbeke (Antwerp, Belgium), W. Vos (Antwerp, Belgium), D. Belmans (Antwerp, Belgium), G. Leemans (Antwerp, Belgium), W. De Backer (Antwerp, Belgium)
| |
Feasibility of a homemonitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis C. Moor (Rotterdam, Netherlands), M. Wapenaar (Rotterdam, Netherlands), J. Miedema (Rotterdam, Netherlands), J. Geelhoed (Rotterdam, Netherlands), P. Chandoesing (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
| |
The correlation between pathological findings of transbronchial lung cryobiopsy and high resolution CT morphology for diffuse parenchymal lung disease patients N. Aiko (Kanagawa, Japan), T. Niwa (Kanagawa, Japan), T. Katano (Kanagawa, Japan), G. Matama (Kanagawa, Japan), K. Isomoto (Kanagawa, Japan), R. Ohtoshi (Kanagawa, Japan), E. Tabata (Kanagawa, Japan), R. Shintani (Kanagawa, Japan), S. Sadoyama (Kanagawa, Japan), H. Yamakawa (Kanagawa, Japan), S. Ikeda (Kanagawa, Japan), H. Nakagawa (Kanagawa, Japan), T. Oda (Kanagawa, Japan), R. Okuda (Kanagawa, Japan), A. Sekine (Kanagawa, Japan), H. Kitamura (Kanagawa, Japan), T. Baba (Kanagawa, Japan), S. Komatsu (Kanagawa, Japan), E. Hagiwara (Kanagawa, Japan), T. Ogura (Kanagawa, Japan)
| |
Dehydroepiandrosterone sulfate plasma levels correlate with lung function, muscle mass and physical performance in fibrotic interstitial lung disease S. Guler (Vancouver, Canada), S. Hur (Vancouver, Canada), S. Lear (Burnaby, Canada), P. Camp (Vancouver, Canada), P. Wilcox (Vancouver, Canada), J. Leung (Vancouver, Canada), C. Ryerson (Vancouver, Canada)
| |
Diagnostic value of BAL lymphocytosis in patients with suspected IPF and indeterminate HRCT pattern V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), M. Ntasiou (Athens, Greece), A. Kefalaki (Athens, Greece), A. Tsonou (Athens, Greece), D. Bouros (Athens, Greece)
| |
Cognitive impairment and depression in patients with Idiopathic Pulmonary Fibrosis R. Elhefny (Cairo, Egypt), A. Elessawy (Cairo, Egypt), H. Shaheen (Fayoum, Egypt), A. Mohamed (Fayoum, Egypt)
| |
Fatigue in IPF measured by the Fatigue Assessment Scale during antifibrotic treatment E. Bendstrup (Aarhus, Denmark), V. Skivild (Aarhus, Denmark), R. Larsen (Aarhus, Denmark), A. Aalestrup (Aarhus, Denmark), I. Terp (Aarhus, Denmark), K. Nordvig (Aarhus, Denmark), T. Prior (Aarhus, Denmark), J. Møller (Aarhus, Denmark)
| |
Survival after respiratory hospitalization in patients with idiopathic chronic fibrosing interstitial pneumonia O. Nishiyama (Osakasayama, Japan), R. Yamazaki (Osakasayama, Japan), S. Saeki (Osakasayama, Japan), H. Sano (Osakasayama, Japan), T. Iwanaga (Osakasayama, Japan), Y. Higashimoto (Osakasayama, Japan), H. Kume (Osakasayama, Japan), Y. Tohda (Osakasayama, Japan)
| |
Effect of pamrevlumab on the UCSD-SOBQ (University of California San Diego–Shortness of Breath Questionnaire) in patients with Idiopathic Pulmonary Fibrosis (IPF) E. Gorina (San Francisco, United States of America), T. Sekayan (San Francisco, United States of America), J. Swigris (Denver, United States of America), P. Lacamera (Boston, United States of America), R. Perez (Louisville, United States of America), M. Hamblin (Kansas City, United States of America), J. Deandrade (Birmingham, United States of America), J. Fitzgerald (Dallas, United States of America), P. Bercz (Pensacola, United States of America), M. Zhong (San Francisco, United States of America), E. Kouchakji (San Francisco, United States of America), P. Yu (San Francisco, United States of America), T. Neff (San Francisco, United States of America)
| |
Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis S. Aldhaheri (Kingston, Canada), O. Moran-Mendoza (Kingston, Canada), L. Mccarthy (Kingston, Canada)
| |
Safety in treating dyspnea with morphine in ILD patients S. Kronborg-White (Aarhus, Denmark), C. Uggerhøj Andersen (Aalborg, Denmark), O. Hilberg (Vejle, Denmark), E. Bendstrup (Aarhus, Denmark)
| |
Visual and fully-automated CT analysis in acute exacerbations of idiopathic pulmonary fibrosis (IPF) L. Kehler (Heidelberg, Germany), T. Norajitra (Heidelberg, Germany), J. Ley-Zaporozhan (Munich, Germany), A. Giannakis (Heidelberg, Germany), R. Rubtsov (Heidelberg, Germany), C. Bauer-Kemeny (Heidelberg, Germany), K. Maier-Hein (Heidelberg, Germany), C. Heussel (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Assessment of survival in patients with idiopathic pulmonary fibrosis (IPF) using quantitative HRCT indexes S. Torrisi (Catania, Italy), S. Palmucci (Catania, Italy), R. Rosso (Catania, Italy), M. Schisano (Catania, Italy), M. Pavone (Catania, Italy), A. Vancheri (Catania, Italy), G. Sambataro (Catania, Italy), C. Crimi (Catania, Italy), A. Stefano (PalermoPaPCatania, Italy), G. Russo (Palermoatania, Italy), C. Vancheri (Catania, Italy)
| |
Frailty is an independent predictor of number and length of hospitalizationsin patients with fibrotic ILD S. Guler (Vancouver, Canada), J. Kwan (Vancouver, Canada), P. Wilcox (Vancouver, Canada), C. Ryerson (Vancouver, Canada)
| |
Risk Factors for Mortality in Patients with Idiopathic Pulmonary Fibrosis Followed at Intensive Care Unit due to Acute Respiratory Failure B. Uysaler (Izmir, Turkey), P. Ekren (Izmir, Turkey), F. Bacakoglu (Izmir, Turkey), N. Mogulkoc Bishop (Izmir, Turkey)
| |